

# StÃ©phane de Botton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6284259/publications.pdf>

Version: 2024-02-01

43  
papers

5,322  
citations

257450

24  
h-index

302126

39  
g-index

45  
all docs

45  
docs citations

45  
times ranked

4704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
2	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
3	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. <i>Cancer Discovery</i> , 2017, 7, 478-493.	9.4	350
4	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. <i>Blood</i> , 2017, 130, 732-741.	1.4	300
5	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 300-305.	2.8	292
6	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	1.4	266
7	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019, 133, 676-687.	1.4	262
8	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 185-193.	1.6	227
9	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 1519-1531.	27.0	186
10	Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2. <i>JAMA Oncology</i> , 2018, 4, 1106.	7.1	157
11	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. <i>Nature Medicine</i> , 2018, 24, 1167-1177.	30.7	157
12	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 1894-1905.	5.2	129
13	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	1.6	118
14	An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. <i>Journal of Experimental Medicine</i> , 2009, 206, 1701-1707.	8.5	75
15	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.	1.4	57
16	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
17	Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 343-343.	1.4	44
18	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	1.6	37
20	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	1.4	37
21	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i>-mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	1.4	36
22	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021, 137, 524-532.	1.4	33
23	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	2.8	32
24	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
25	Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	1.4	27
26	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	1.4	23
27	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. <i>Leukemia</i> , 2018, 32, 2008-2081.	7.2	18
28	Azacitidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1659-1665.	1.3	15
29	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. <i>Blood</i> , 2019, 134, 2414-2416.	1.4	14
30	Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. <i>HemaSphere</i> , 2019, 3, e203.	2.7	13
31	Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 735-746.	4.1	12
32	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with <i>IDH2</i> mutations using historical data and propensity score matching analysis. <i>Cancer Medicine</i> , 2021, 10, 6336-6343.	2.8	6
33	A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.. <i>Blood</i> , 2009, 114, 632-632.	1.4	6
34	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 421-428.	0.7	3
35	Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e986-e989.	0.4	3
36	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , 2017, 54, 12-16.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 429-438.	0.7	2
38	Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. Blood, 2019, 134, 3722-3722.	1.4	1
39	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
40	IDH Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S3-S4.	0.4	0
41	SOHO State of the Art Updates and Next Questions: IDH Inhibition. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 567-572.	0.4	0
42	CXCR4 Blockade as a New Targeted Therapy for Acute Myeloide Leukemia Characterised by High Cell Surface Density of CXCR4.. Blood, 2009, 114, 4570-4570.	1.4	0
43	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). Blood, 2015, 126, 2893-2893.	1.4	0